
EBCC 2026
7 interviews1 hr 1 min
European Breast Cancer Conference
Interviews and expert commentary from EBCC 2026 — study authors and key opinion leaders discuss the findings and their clinical implications.

Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer
Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective…

Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard…

Elisa Agostinetto MD; 2026 EBCC: Circulating Tumor DNA Trumps Clinical Prognostic Markers After Neoadjuvant Therapy for Patients with Early Breast Cancer
Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast…

Kerstin Wimmer MD; 2026 EBCC: Polyurethane-Coated Implants Reduce Capsular Contracture Risk after Mastectomy with Radiotherapy for Breast Cancer
Kerstin Wimmer MD, at the 2026 EBCC, discussed the OPBC-09 PRExRT study findings, revealing that polyurethane-coated breast implants significantly reduce capsular contracture risk for breast cancer…

Fatima Cardoso MD; 2026 EBCC: OASIS-4 Trial Finds Elinzanetant Cuts Vasomotor Symptoms (“Hot Flashes”) in Endocrine Therapy-Treated Patients with Breast Cancer
At EBCC 2026, Fatima Cardoso MD discussed the OASIS-4 trial, revealing elinzanetant greatly reduced vasomotor symptoms ("hot flashes") in breast cancer patients receiving endocrine therapy. This dual…

Philip Poortmans MD PhD; 2026 EBCC: European Breast Cancer Conference: Focus on Therapy De-escalation and Individualization
This episode features Philip Poortmans MD PhD, University of Antwerp & Iridium Netwerk, discussing key themes from the 2026 European Breast Cancer Conference. He focuses on individualizing breast…

Tess Snellen MD; 2026 EBCC: Molecular Test Distinguishes Ipsilateral Second Primary from Recurrent Breast Cancer
Tess Snellen MD, from the Netherlands Cancer Institute, presents key findings at the EBCC 2026 regarding a molecular test. This innovative test utilizes next-generation sequencing to precisely…